Tag: daraxonrasib
-
Revolution Medicines Wins FDA Approval for Rasonque in Metastatic Pancreatic Cancer
The FDA approved Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma after Phase 3 RASolute 302 showed a major survival benefit over chemotherapy.
-
How Daraxonrasib Blocks Active RAS Across Multiple Mutations
Daraxonrasib forms a cyclophilin A-dependent tri-complex with active RAS, blocking downstream signaling across multiple RAS variants.